No startup division Although completely immune to market uncertainty in 2022, with the exception of perhaps AI, some have proven more resilient than others.Biotech is one of the luckiest companies .
According to Pitchbook data, the sector will record 1,054 US-based deals in 2022, worth a total of $30.7 billion. Those figures fell short of the 1,415 biotech deals valued at a total of $39 billion that closed in 2021. But the decline wasn’t the worst we found: biotech outperformed many other sectors, including fintech (37.7%), consumer tech (53%) and enterprise tech (33%). also saw a modest year-on-year decline in investment (21%). %).
Comparing sector results to 2021 is somewhat questionable. Last year he was worth $29.6 billion, compared to the more conservative 1,143 biotech deals in 2020.
US biotech deals set new records in 2022 with both a median deal size of $33.5 million and a median valuation of $38 million.
Investors in biotech told TechCrunch that while they certainly felt the overall economic strain last year, they noticed that tourist investors, like other sectors, were staying away from the category. Many said they were not surprised that the category performed better than some other sectors. The industry is buzzing for several important reasons.
